Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jun 19;14(3):208.
doi: 10.1186/bcr3139.

Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer

Vikram K Jain  1 , Nicholas C Turner
Affiliations
Review

Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer

Vikram K Jain et al. Breast Cancer Res. .

Abstract

Activation of the fibroblast growth factor receptor pathway is a common event in many cancer types. Here we review the role of fibroblast growth factor receptor signalling in breast cancer, from SNPs in FGFR2 that influence breast cancer risk and SNPs in FGFR4 that associate with breast cancer prognosis, and potential therapeutic targets such as receptor amplification and aberrant autocrine and paracrine ligand expression. We discuss the multiple therapeutic strategies in preclinical and clinical development and the current and future challenges to successfully targeting this pathway in cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Alterations in the FGFR signalling pathway that influence breast cancer. Single nucleotide polymorphisms (SNPs) influence breast cancer risk (FGFR2), and prognosis in established cancers likely through effects on motility and invasive capacity (FGFR4). Somatic alterations presenting potential therapeutic targets include amplification of FGFR1 and FGFR2, and aberrant FGF2 ligand expressed in a paracrine or autocrine fashion.
See this image and copyright information in PMC

References

    1. Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011;17:1147–1159. doi: 10.1158/1078-0432.CCR-10-1869. - DOI - PMC - PubMed
    1. Di Cosimo S, Bendell JC, Cervantes-Ruiperez A, Roda D, Prudkin L, Stein MN, Leighton-Swayze A, Song Y, Ebbinghaus S, Baselga J. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors [abstract 3008] J Clin Oncol. 2010;28(Suppl):15s..
    1. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–129. doi: 10.1038/nrc2780. - DOI - PubMed
    1. Kimelman D, Kirschner M. Synergistic induction of mesoderm by FGF and TGF-beta and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell. 1987;51:869–877. doi: 10.1016/0092-8674(87)90110-3. - DOI - PubMed
    1. De Moerlooze L, Spencer-Dene B, Revest JM, Hajihosseini M, Rosewell I, Dickson C. An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development. 2000;127:483–492. - PubMed

Publication types

MeSH terms

Substances